Diabetes Prevention Program Outcomes Study

PHASE3UnknownINTERVENTIONAL
Enrollment

2,779

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

October 31, 2024

Study Completion Date

January 31, 2025

Conditions
Diabetes MellitusCancerCVD
Interventions
BEHAVIORAL

DPPOS Group Lifestyle

Quarterly group lifestyle sessions

DRUG

Metformin

Administered as 850mg twice per day, masked in DPP and open label in DPPOS

BEHAVIORAL

DPPOS Boost Lifestyle

In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.

BEHAVIORAL

Intensive Lifestyle Group Session

16 session curriculum in group format. In DPP delivered to ILS as individual sessions

Trial Locations (1)

20852

George Washington University, Rockville

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute on Aging (NIA)

NIH

collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Eye Institute (NEI)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

collaborator

Office of Research on Women's Health (ORWH)

NIH

collaborator

Centers for Disease Control and Prevention

FED

collaborator

American Diabetes Association

OTHER

collaborator

Indian Health Service (IHS)

FED

collaborator

General Clinical Research Program

UNKNOWN

collaborator

US Department of Veterans Affairs

FED

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH